Selective Estrogen Receptor Modulators

Keywords

Raloxifene, Tamoxifen, Selective estrogen receptor modulator, Partial agonist, Estrogen receptor

References

• Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarraysJosé Luis Moreno Becerra, Rocío Peña Vázquez — 2002
• Breast cancer: from estrogen to androgen receptorJuan Ignacio Sánchez Gutiérrez — 2002
• An issue of tissues: divining the split personalities of selective estrogen receptor modulatorsNeil J. McKenna, Bert W. O’Malley — 2000
• Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen.M. Berry, Daniel METZGER, Pierre Chambon — 1990
• The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles.Heather E. Cunliffe, Markus Ringnér, Sven Bilke — 2003
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.Lajos Pusztai, Mark Ayers, James Stec — 2003
• Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.Paul Webb, Gabriela N. Lopez, Rosalie M. Uht — 1995
• 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.Takashi Suzuki, Andrew D. Darnel, Jun‐ichi Akahira — 2001
• Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation*Eileen M. McInerney, Benita S. Katzenellenbogen — 1996
• An Antiestrogen-responsive Estrogen Receptor-α Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen*Paul Webb, Phuong Nguyen, Cathleen D. Valentine — 2000
• The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.Twila A. Jackson, Jennifer K. Richer, David L. Bain — 1997
• Combinatorial Control of Gene Expression by Nuclear Receptors and CoregulatorsNeil J. McKenna, Bert W. O’Malley — 2002
• Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors.Hyeseong Cho, Susan M. Aronica, Benita S. Katzenellenbogen — 1994
• Estrogen Response Elements Can Mediate Agonist Activity of Anti-estrogens in Human Endometrial Ishikawa Cells*Annie Barsalou, Wenli Gao, Silvia I. Anghel — 1998
• Suppression of the transformed phenotype of breast cancer by tropomyosin-1.K Mahadev — 2002
• Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors.Susan M. Aronica, BENITA S. KATZENELLENBOGEN — 1991
• Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.Monica M. Montano, Kirk Ekena, Kristopher Krueger — 1996
• Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated Pathway*Dorry L. Segev, Thanh U. Ha, Trinh T. Tran — 2000
• Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney.Scott A. Jelinsky, Heather A. Harris, Eugene L. Brown — 2003
• Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.J D Fan, B L Wagner, Donald P. McDonnell — 1996

Cited by

• Molecular responses to xenoestrogens: mechanistic insights from toxicogenomics.Hyoann Choi, Jobling, Annemaree Carroll — 2005
• The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.Richard L. Buckner, David F. Oetinger, Shareen C. Buckner — 2005
• A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone.I Sh Vesel'skiĭ, Gurkina Ki — 2009
• Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate.J.E. Timperley — 2015
• G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 AxisIsidoro Pérez Guzmán — 2016
• Estrogen receptor phenotypes defined by gene expression profiling.Marleen Kok, Sabine C. Linn, Marc J. van de Vijver — 2009
• Estudio funcional y molecular del canal Maxi-Cl activado por antiestrógenosBahamonde Santos, María Isabel — 2004
• Role of estrogens in the male reproductive tract.E R Simpson, Stephen J. McPherson, Margaret E. E. Jones — 2004
• Design, Synthesis, and Process Chemistry Studies of Agents Having Anti-Cancer PropertiesAmarjit Luniwal — 2011
• Prevention and Treatment of Postmenopausal OsteoporosisR.B. Hallworth — 1998
• From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Victoria Shang Wu, Noriko Kanaya, Chiao Lo — 2015
• Identification and characterization of estrogen receptor-regulated gene expression programsDaniel Barnett — 2010
• Mechanical evaluation of effect of grape seed proanthocyanidins extract on debilitated mandibles in rats.Masaru Gunjima — 2004
• Nuclear Receptors as Drug TargetsE. Ottow, H. Weinmann — 2008
• Androgens in Health and DiseaseCarrie Bagatell, William J. Bremner — 2003
• Efficacy of tamoxifen and thymoquinone on tumor development, lipid peroxidation, and total antioxidant capacity in DMBA induced mammary carcinoma in female Sprague-Dawley ratsNadiah S. Alotaibi — 2013
• Molecular Mechanisms of Protein Kinase A Signaling Pathway on Estrogen Receptor Action in Breast CancerMariam Al-Dhaheri — 2006
• A novel four- and pseudo-five-component reaction: unexpected efficient one-pot synthesis of 4H-thiopyran derivativesAkbar Mobinikhaledi, Mohammad Ali Bodaghifard, Sajad Asadbegi — 2016
• Computational approaches to analyze next generation sequencing dataDe Filippo, Maria Rosaria — 2013
• Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.Julie F. McManus, Rachel A. Davey, Helen E. MacLean — 2008

Related papers

• Growth Inhibition of Human Uterine Leiomyoma Cells by Selective Estrogen Receptor ModulatorMin Young Lee, Chi‐Heum Cho, Sang Hoon Kwon — 2004
• Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.Douglas B. Muchmore — 2000
• [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].Hiroaki Ohta — 2008
• [Clinical experience with raloxifene].J Szũcs, Imre Pávó, N Jurida — 2000
• Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?Philip N. Sambrook — 2005
• Raloxifene: A Selective Estrogen Receptor Modulator for Reducing the Risk of Invasive Breast Cancer in Postmenopausal WomenVictor G. Vogel — 2007
• In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.Bruce Mitlak, Fredric J. Cohen — 1997
• S35 The clinical promise of the selective estrogen receptor modulator, raloxifene HCI and the postmenopausal womanP. W. Anderson — 1996
• Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.Meng Kian Tee, Inez Rogatsky, Christina Tzagarakis-Foster — 2003